Q3 2025 · 13F-HR
Sio Capital Management, LLCholdings as filed
Filed 2025-11-13 · accession 0001214659-25-016415
$395.2M
Reported value
51
Positions
2025-09-30
Period end
The Brief · Sio Capital Management, LLC · Q3 2025
AI · grounded in 13F
Sio Capital Management, LLC established a new position in MMS valued at $50.9M. The fund also initiated new stakes in CELC for $38.9M and SNY for $26.6M. Additional new positions include DNTH, ALKS, and IRON.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 577933104 | MMS | MAXIMUS INC | $50.9M | 12.9% | 557,615 | Common | SOLE |
| 15102K100 | CELC | CELCUITY INC | $38.9M | 9.83% | 786,526 | Common | SOLE |
| 80105N105 | SNY | SANOFI SA | $26.6M | 6.72% | 562,703 | Common | SOLE |
| 252828108 | DNTH | DIANTHUS THERAPEUTICS INC | $22.7M | 5.75% | 577,750 | Common | SOLE |
| G01767105 | ALKS | ALKERMES PLC | $20.2M | 5.12% | 674,840 | Common | SOLE |
| 254604101 | IRON | DISC MEDICINE INC | $18.8M | 4.76% | 284,787 | Common | SOLE |
| 58933Y105 | MRK | MERCK & CO INC | $14.9M | 3.77% | 177,300 | Common | SOLE |
| 806407102 | HSIC | HENRY SCHEIN INC | $14.5M | 3.68% | 219,207 | Common | SOLE |
| 15135B101 | CNC | CENTENE CORP DEL | $13.8M | 3.50% | 387,600 | Common | SOLE |
| 49177J102 | KVUE | KENVUE INC | $13.7M | 3.47% | 844,000 | Common | SOLE |
| 09061G101 | BMRN | BIOMARIN PHARMACEUTICAL INC | $12.2M | 3.09% | 225,114 | Common | SOLE |
| 37733W204 | GSK | GSK PLC | $11.6M | 2.94% | 268,873 | Common | SOLE |
| 10919W405 | DRUG | BRIGHT MINDS BIOSCIENCES INC | $11.6M | 2.93% | 190,764 | Common | SOLE |
| 405024100 | HAE | HAEMONETICS CORP MASS | $9.7M | 2.44% | 198,035 | Common | SOLE |
| 03843E104 | AQST | AQUESTIVE THERAPEUTICS INC | $8.4M | 2.12% | 1,498,095 | Common | SOLE |
| 483497103 | KALV | KALVISTA PHARMACEUTICALS INC | $8.3M | 2.11% | 683,819 | Common | SOLE |
| 03675P102 | AVR | ANTERIS TECHNOLOGIES GLOBAL | $8.0M | 2.02% | 1,772,601 | Common | SOLE |
| 22663K107 | CRNX | CRINETICS PHARMACEUTICALS IN | $7.3M | 1.84% | 174,841 | Common | SOLE |
| 90240B106 | TYRA | TYRA BIOSCIENCES INC | $7.2M | 1.82% | 514,947 | Common | SOLE |
| 75383L102 | RAPP | RAPPORT THERAPEUTICS INC | $5.5M | 1.39% | 185,265 | Common | SOLE |
| G6674U108 | NVCR | NOVOCURE LTD | $5.3M | 1.35% | 413,829 | Common | SOLE |
| 00182C103 | ANIP | ANI PHARMACEUTICALS INC | $5.1M | 1.29% | 55,723 | Common | SOLE |
| 28036F105 | EWTX | EDGEWISE THERAPEUTICS INC | $5.0M | 1.26% | 307,181 | Common | SOLE |
| 879369106 | TFX | TELEFLEX INCORPORATED | $4.9M | 1.24% | 40,057 | Common | SOLE |
| 829214105 | SLP | SIMULATIONS PLUS INC | $4.8M | 1.22% | 320,307 | Common | SOLE |
| N71542109 | PRQR | PROQR THERAPEUTICS N V | $4.4M | 1.12% | 2,075,139 | Common | SOLE |
| 82537J108 | SI | SHOULDER INNOVATIONS INC | $4.4M | 1.11% | 350,000 | Common | SOLE |
| 69353Y103 | PMVP | PMV PHARMACEUTICALS INC | $3.7M | 0.93% | 2,636,548 | Common | SOLE |
| 81734D104 | SEPN | SEPTERNA INC | $3.6M | 0.90% | 189,199 | Common | SOLE |
| 45166A102 | IDYA | IDEAYA BIOSCIENCES INC | $3.4M | 0.86% | 124,230 | Common | SOLE |
| 01626L204 | ALGS | ALIGOS THERAPEUTICS INC | $3.3M | 0.83% | 335,937 | Common | SOLE |
| 29479A108 | ERAS | ERASCA INC | $3.0M | 0.76% | 1,369,748 | Common | SOLE |
| 92764N102 | VIR | VIR BIOTECHNOLOGY INC | $2.7M | 0.69% | 478,343 | Common | SOLE |
| 805111101 | SVRA | SAVARA INC | $2.6M | 0.66% | 726,851 | Common | SOLE |
| 92332V107 | VTYXUSD | VENTYX BIOSCIENCES INC | $2.6M | 0.65% | 829,178 | Common | SOLE |
| 64130M209 | — | NEUROONE MED TECHNOLOGIES CO | $2.1M | 0.53% | 2,360,635 | Common | SOLE |
| 690469101 | OVID | OVID THERAPEUTICS INC | $1.9M | 0.47% | 1,427,495 | Common | SOLE |
| 107924102 | BBOT | BRIDGEBIO ONCOLOGY THERAPEUT | $1.5M | 0.38% | 130,628 | Common | SOLE |
| 21077P108 | CNTX | CONTEXT THERAPEUTICS INC | $1.3M | 0.33% | 1,341,636 | Common | SOLE |
| 81727U105 | SENS1GBP | SENSEONICS HOLDINGS INC | $1.0M | 0.26% | 2,315,749 | Common | SOLE |
| 872381108 | TELA | TELA BIO INC | $948,087 | 0.24% | 636,300 | Common | SOLE |
| 05338F306 | AVTX | AVALO THERAPEUTICS INC | $917,319 | 0.23% | 72,173 | Common | SOLE |
| 344174107 | FHTX | FOGHORN THERAPEUTICS INC | $600,927 | 0.15% | 122,889 | Common | SOLE |
| 60785L207 | — | MODULAR MED INC | $549,920 | 0.14% | 785,824 | Common | SOLE |
| B6S7WD106 | NYXH | NYXOAH S A | $233,859 | 0.06% | 50,839 | Common | SOLE |
| 10170A100 | BOLD | BOUNDLESS BIO INC | $201,325 | 0.05% | 163,679 | Common | SOLE |
| 03836J201 | APRE | APREA THERAPEUTICS INC | $165,529 | 0.04% | 112,223 | Common | SOLE |
| 880881107 | 430 | TERNS PHARMACEUTICALS INC | $75,851 | 0.02% | 10,100 | Common | SOLE |
| 65343E207 | NXTC | NEXTCURE INC | $64,108 | 0.02% | 10,940 | Common | SOLE |
| 77313F114 | RCKTW | ROCKET PHARMACEUTICALS INC | $14,440 | 0.00% | 400,000 | Common | SOLE |
| 44486Q111 | HUMAW | HUMACYTE INC | $12,240 | 0.00% | 49,998 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.